Conceivable Life Sciences

We have tracked the fertility space for years, looking for the right company to address one of the most universal and underserved challenges in medicine. Infertility affects 1 in 6 people worldwide. It crosses every income level and geography. And yet the technology used to treat it has barely changed since the 1970s, leaving a Nobel Prize-winning therapy out of reach for the vast majority who need it.

What drew us to Conceivable was simple: this is not an unsolvable problem. It is an engineering problem. And the founding team had the domain depth and the ambition to solve it properly, not at the margins, but by rebuilding the IVF lab from scratch.

Together they built AURA: a 17-foot, 4,500-pound robotic assembly line and the only system in the world capable of performing every step of IVF outside the human body. Six integrated instruments handle the full process, from sperm preparation to embryo storage, standardizing more than 200 steps that have long depended on manual skill. The business model is as radical as the technology. By partnering with OB/GYNs, Conceivable enables clinicians to offer IVF without a multimillion-dollar lab, designed to run 2,000 cycles a year with just three staff members, and targeting a 70% reduction in cost per cycle.

The clinical results have followed. An earlier IRB study produced 21 pregnancies at a 51% success rate, without genetic testing, rivalling the world's top fertility clinics. AURA has since helped bring 20 children to life across clinical trials. The peer-reviewed paper on the first fully automated ICSI live birth won the Robert G. Edwards Prize for best original paper of 2025 and became the most downloaded paper in Reproductive BioMedicine Online that year, with over 16,000 downloads. When industry leaders visit the live lab in Mexico City, they consistently describe the same thing: a sense of inevitability.

Infertility affects roughly 1 in 6 people worldwide, across every income level and geography, yet IVF, a Nobel Prize-winning therapy, remains out of reach for about 95% of those who need it. The procedure has barely changed since the 1970s and stays expensive and concierge by design, capping access far below demand.

The founders brought decades of experience building category-defining companies across technology, hospitality, and life sciences. Since 2018 they have focused exclusively on fertility, creating the world's only FDA-vetted automated technology for managing frozen eggs and embryos at TMRW Life Sciences, and investing in multiple companies at the intersection of AI and IVF. They partnered with Alejandro Chavez-Badiola, a reproductive endocrinologist, fertility clinic medical director, and co-founder of a leading AI platform for IVF, one of the few people in the world who has operated at the frontier of both the science and the clinical practice.

Conceivable is the first company to automate the entire IVF lab. Its AURA platform covers every stage of the process across six integrated instruments, using single-cell manipulation robotics, machine vision, microscopy, and piezo technology to standardize more than 200 steps that have historically depended on manual, artisanal skill. The patent portfolio spans cell manufacturing and IVF. No other company has done this end to end.

The business model is as important as the technology. By partnering with OB/GYNs, Conceivable enables clinicians to offer IVF without building or running multimillion-dollar labs. That shifts fertility care from a concierge service available to a few into a scalable offering accessible to many, with a credible path to cutting the cost of a cycle by 70%.

The proof is no longer theoretical. In a peer-reviewed study published in Human Reproduction in December 2025, the integrated robotic workflow achieved a 64.3% fertilization rate and five live births from twelve single embryo transfers. Robotic IVF has now produced at least 20 children in clinical trials. The Washington Post told the story of Alin Quintana, who could not afford traditional IVF after losing a prior pregnancy, joined the Mexico City trial in June 2025, and gave birth in early 2026.

Conceivable has raised $70 million in total, including a $50 million Series A in September 2025 led by Advance Venture Partners, with ARTIS Ventures, ACME, Stride, and others reinvesting. A 100-patient IRB pilot is running in Mexico City. US commercial launch is targeted for H2 2026.